Cargando…
Risk of immune-related diarrhea with PD-1/PD-L1 inhibitors in different cancer types and treatment regimens
Objective: To compare the incidence and severity of diarrhea among different tumor types and treatment regimens, and also compared with CTLA-4 inhibitors in randomized controlled trials. Methods: MEDLINE, PMC database and EMBASE were retrieved until December 2018. Studies were eligible if they were...
Autores principales: | Zhao, Lei, Yu, Jing, Wang, Jing, Li, Huihui, Che, Juanjuan, Cao, Bangwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930395/ https://www.ncbi.nlm.nih.gov/pubmed/31892971 http://dx.doi.org/10.7150/jca.32724 |
Ejemplares similares
-
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019) -
Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis
por: Ma, Yan, et al.
Publicado: (2022) -
Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017) -
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017) -
PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)